Identification
Symbol
NYXH
ISIN code
BE0974358906
LEI code
5493002O1ESKZ18OXR80
Exchange / Market
Euronext
Trading location
Brussels
Capitalization compartment
Compartment B
ICB
20102010 Medical Equipment
Website address
Operation
IPO date
IPO type
Initial Public offering
Operation calendar

Revised timetable:

  • Initially expected on 22/09/2020, the closing date of the offer period is now expected on 16/09/2020.
  • Initially expected on 24/09/2020, the first trading date is now expected on 18/09/2020.
  • Initially expected on 25/09/2020, the settlement date is now expected on 21/09/2020.
     
Price range
EUR 14.00 - EUR 17.00 (inclusive)

Company profile

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah SA's innovative solution platform is based on the Genio® system, a CE-Mark validated, user-centered neurostimulation therapy for obstructive sleep apnea, the world's most common sleep disordered breathing condition.

Source: Cofisem - Last Update: 24 Sep 2020
Key Executives
Chief Executive Officer Olivier Taelman
Chief Financial Officer Fabian Suarez Gonzalez
Source: Cofisem - Last Update: 10 Sep 2020
Key figures
Millenium 2019 2018 2017
Net sales
Income from ordinary activities
Operating income -6,516 -8,450 -10,143
Cost of financial indebtedness net 617 509 100
Equity-accounted companies contribution to income
Net profit from discontinued activities
Net income -7,255 -9,079 -10,371
Net income (Group share) -7,255 -9,079 -10,371
Fiscal year end 12.19 12.18 12.17
Length of fiscal year (month)
Currency & Unit EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 24 Sep 2020
Shareholder information
Cochlear Investments Pty Ltd 17.90 %
Gilde Healthcare Partners 14.80 %
Robert Taub 12.76 %
Together Partnership 11.44 %
Jürgen Hambrecht 4.75 %
ResMed, Inc. 3.59 %
Source: Cofisem - Last Update: 10 Sep 2020